Francois Binette

Dr. François Binette is Vice President of Research and Business Development, for OrthoCyte Corp, the orthopedic subsidiary of Biotime Inc. As head of OrthoCyte, Dr. Binette is responsible for all development and partnering activities for the subsidiary. With over 20 years of experience in regenerative medicine therapy development, Dr. Binette helped pioneer the first FDA BLA-approved cell therapy product for human use while at Genzyme.  He then led R&D for Biosyntech, a startup biomaterials company in Montreal and brought numerous corporate partnership deals leading up to a public offering. With a passion for innovation making a real impact on patients, Dr. Binette then joined DePuy, the orthopedic franchise of Johnson and Johnson where he led several innovative regenerative medicine combination product development initiatives from bench top to approved clinical trials in US an Europe. Following JNJ, Dr. Binette joined the Spinal and Biologics business unit of Medtronic, the world largest medical device company, after which he founded Rediens Inc, a spine therapy start up company in California. Dr Binette received his PhD from Laval University in Québec City, followed with post-doctoral training at the Sanford-Burnham institute in La Jolla, and Harvard Medical School in Boston.